Caixin Global – Latest China News & Headlines

Home >


CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

JD Logistics Takes Pitches from Banks for Planned Hong Kong IPO in 2021
New Rules Derail Mega Livestreaming E-Commerce Deal
Trending in China: Why Are People Queuing Eight Hours and Paying $30 for a Cup of Milk Tea?
Trending in China: Teacher Assaulting Children Raises Question About Role of Volunteers in Education
‘Look, No Hands!’ - AutoX Rolls Out China’s First Self-Driving Fleet Without Safety Drivers
U.S. Firms Deny Selling to China Military, as Washington Prepares New Blacklist
Baker Bros. Advisors Sells ADSs in BeiGene Just Months After Buying Shares
Trending in China: Sharing Students’ Grades Online – The Fine Line Between Motivation and Public Shaming
Tesla Rival Li Auto Plans New Share Sale to Bankroll R&D
Alibaba Logistics Arm Chills with Ethiopian Airlines to Transport Covid-19 Vaccines
U.S. Blacklist of Chinese Tech Firms Continues to Grow
China's Bluetooth Audio Chip King Set For $741m Shanghai IPO
U.S.-Blacklisted Hikvision Zooms in on COVID Tracking Demand Reports First Quarterly Profit of 2020 as Travel Recovers
Xiaomi Raises Nearly $4 Billion Through Sale of Shares and Bonds
Baidu Leads China in AI Patent Applications and Ownership
Trending in China: Now Forbidden on China’s Trains
Chinese Biopharma Firm Pegbio Nets $122m in Pre-IPO Round From YF Capital, Yingke, Others
NEV Makers Nio and Xpeng Keep Revving Up Sales, But Investor Unimpressed
Britain Bans Installation of New Huawei 5G Equipment from September 2021 in Major U-Turn
Chinese Biotech Firm Gracell Nets $100m From Wellington, OrbiMed, Others

By DealStreetAsia / Oct 30, 2020 12:24 PM / Finance

Chinese clinical-stage biopharmaceutical firm Gracell Biotechnologies Inc. has completed a $100 million Series C round co-led by the US investment company Wellington Management, New York-based OrbiMed Healthcare Fund Management, and VC firm 5Y Capital (formerly Morningside Venture Capital), the investee company said on Wednesday.

Vivo Capital, a new investor in Gracell, participated in the round, along with existing investors such as Singapore’s Temasek, Shanghai-based Lilly Asia Ventures (LAV), and US Kington Capital’s King Star Capital.

The $100 million round comes nearly two years after Gracell pocketed a $85 million Series B financing from Temasek, LAV, King Star Capital, Kington Capital, and others in February 2019.

The latest proceeds will be used to support Gracell’s research and development, besides clinical-stage pipeline candidates.

With headquarters in Shanghai and GMP (good manufacturing practices) in Suzhou, Gracell targets to deliver safe and affordable immunotherapy to solve CAR-T industry hurdles. Since its inception in 2017, Gracell has been leveraging two proprietary platforms, FasTCAR and TruUCAR, to develop a pipeline of autologous and allogeneic cell therapy candidates. Its research primarily caters to hematologic malignancies and solid tumors.

Its flagship TruUCAR allogeneic product candidate, GC027, is under phase 1 trial in China for the treatment of relapsed or refractory T cell acute lymphoblastic leukemia, it said. “Our passion is to bring transformative CAR-T cell therapies to a broader group of patients by developing products that are efficacious and can be made widely available,” said Dr. William Wei Cao, founder, chairman and CEO of Gracell.

Gracell had closed two rounds of funding in 2017, with an undisclosed angel round from Tonghe Capital and Shanghai Zhaoheng Investment Fund in August, followed by a 70 million yuan ($10 million) Series A round financing from 6 Dimensions Capital.

Contact editor Marcus Ryder (

Related: Jack Ma-Backed Biotech Firm Considers Hong Kong IPO

Share this article
Open WeChat and scan the QR code